GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2006

Esprit Grants Depomed $10M License Fee

  • Esprit paid Depomed a $10 million license fee payment due under the parties' license agreement for ProQuin® XR, a treatment for uncomplicated urinary tract infections. ProQuin XR, an extended release formulation of the antibiotic ciprofloxacin, was developed by Depomed and exclusively licensed in the U.S. to Esprit.

    In addition, Depomed and Esprit have agreed to commence discussions toward a mutually agreeable restructuring of their license agreement after the new year. In the meantime, the existing agreement will remain in effect.
    Depomed also agreed to withdraw the notice of breach and demand for arbitration related to the license agreement.

     



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?